Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 65Neoplasms 50Colorectal Neoplasms 49Prostatic Neoplasms 39Carcinoma, Non-Small-Cell Lung 39Lung Neoplasms 34Pancreatic Neoplasms 27Leukemia, Myeloid, Acute 23Multiple Myeloma 21Recurrence 17Carcinoma, Hepatocellular 17Uterine Cervical Neoplasms 16Ovarian Neoplasms 15Neoplasm Metastasis 14Squamous Cell Carcinoma of Head and Neck 13Head and Neck Neoplasms 13Triple Negative Breast Neoplasms 12Stomach Neoplasms 12Melanoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Glioblastoma 11Endometrial Neoplasms 11Rectal Neoplasms 10Carcinoma, Renal Cell 10Brain Neoplasms 10Advanced Solid Tumors 10Lymphoma, B-Cell 9Disease 9Colonic Neoplasms 9Esophageal Neoplasms 8

Interventions

ribociclib 1exemestane 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Letrozole 1Drug Therapy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Anatomic Stage II Breast Cancer AJCC v8 × 30 days × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡